2021; Zhang et al. 2019). Primarily acting as a protein kinase to stimulate HIF‐1α, the dimeric form helps proinflammatory macrophages and cancer cells undergo aerobic glycolytic metabolic reprogramming. (Shirai et al. 2016; Palsson‐McDermott et al. 2015). Huang et al. conducted a study demonstrating that shikonin displays nonspecific inhibitory effects on both active forms (Huang et al. 2022). The gene discussed is HIF1A; the disease is cancer.